Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ardelyx, Inc.

< Previous 1 2 Next >
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
From Ardelyx, Inc.
Via GlobeNewswire
Tickers ARDX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.